(Q34275547)

1 August 2017

1 reference

title

Understanding and preventing drug interactions in elderly patients (English)

1 reference

1 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607376

30 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

30 March 2024

author name string

Jeffrey C. Delafuente

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607376

30 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14607376

30 March 2024

publication date

1 November 2003

1 reference

full work available at URL

1 August 2017

https://api.elsevier.com/content/article/PII:S1040842803002038?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

https://api.elsevier.com/content/article/PII:S1040842803002038?httpAccept=text/plain

30 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Critical Reviews in Oncology Hematology

30 March 2024

published in

1 reference

1 August 2017

48

1 reference

1 August 2017

133-143

1 reference

1 August 2017

2

1 reference

Important drug-drug interactions in the elderly

1 August 2017

1

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Adverse drug events in high risk older outpatients

30 March 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Incidence and preventability of adverse drug events in nursing homes

30 March 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Characterization of geriatric drug-related hospital readmissions

30 March 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Polypharmacy in the aged. Practical solutions

30 March 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

National trends in use of medications in office-based practice, 1985-1999

30 March 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Direct-to-consumer prescription drug advertising and the public

30 March 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Direct-to-consumer advertisements for prescription drugs: what are Americans being sold?

30 March 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

The potential for drug interactions

30 March 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Discrepancies in the use of medications: their extent and predictors in an outpatient practice

30 March 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Altered pharmacodynamics in the elderly

30 March 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

30 March 2024

Pharmacogeriatrics

14

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population

30 March 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Prospective evaluation of adverse drug interactions in the emergency department

30 March 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department

30 March 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients

30 March 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Impact of inappropriate drug use on mortality and functional status in representative community dwelling elders

30 March 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Effect of metoclopramide on digoxin absorption from tablets and capsules

30 March 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people

30 March 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Drug-induced cognitive impairment in the elderly

30 March 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Psychotropic drug use and the risk of hip fracture

30 March 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Risk factors for falls among elderly persons living in the community

30 March 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Implications of cytochrome P450 interactions when prescribing medication for hypertension

30 March 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Clinically significant drug interactions.

30 March 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Grapefruit juice-drug interactions

30 March 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Grapefruit juice--felodipine interaction in the elderly

30 March 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Effects of grapefruit juice on the pharmacokinetics of sildenafil

30 March 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers

30 March 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients

30 March 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life

30 March 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study

30 March 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Dramatic inhibition of amiodarone metabolism induced by grapefruit juice

30 March 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Grapefruit juice substantially increases plasma concentrations of buspirone

30 March 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy

30 March 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Interaction between grapefruit juice and diazepam in humans.

30 March 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid

30 March 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man

30 March 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Grapefruit juice increases oral nimodipine bioavailability

30 March 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.

30 March 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients

30 March 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis

30 March 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison

30 March 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin

30 March 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Serum creatinine is an inadequate screening test for renal failure in elderly patients

30 March 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients

30 March 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients

30 March 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Effect of quinidine on plasma concentrations of digoxin

30 March 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

Effect of quinidine on plasma concentration of digoxin

30 March 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2003.04.004

30 March 2024

Identifiers

1 reference

1 August 2017

1 reference